Positive top-line Phase 1 data for lead clinical program DNTH103 confirm potent classical pathway inhibition, extended half-life, and a potentially differentiated safety profile Results support DNTH103’s best-in-class potential to be the first subcutaneous, self-administered injection dosed as infrequently as once every two weeks to treat a range of autoimmune disorders Company plans to initiate multiple Phase 2 trials targeting neuromuscular indications in 2024, starting with generalized Myasthenia Gravis in Q1 2024, followed by Multifocal Motor Neuropathy in Q2 2024, and Chronic Inflammatory Demyelinating Polyneuropathy in second half of 2024 Dianthus Therapeutics, Inc.
领先的临床计划DNTH103的正一线1期数据证实了有效的经典途径抑制作用，延长的半衰期以及潜在的差异化安全性结果支持DNTH103成为第一个皮下注射的一流潜力，公司计划于2024年启动针对神经肌肉适应症的多个2期临床试验，首先是2024年的全身性重症肌无力，然后是2024年的多灶性运动神经病，和2024年下半年的慢性炎症性脱髓鞘性多发性神经病Dianthus Therapeutics，Inc。
will begin trading on Nasdaq as DNTH with approximately $184 million of cash runway expected to fund operations into Q2 2026 NEW YORK and WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced positive top-line Phase 1 data for DNTH103 validating its best-in-class potential as a selective classical pathway inhibitor targeting only the active form of the C1s protein.
将以DNTH的形式在纳斯达克开始与约1.84亿美元的cash跑道交易，预计将为2026年第二季度纽约和马萨诸塞州沃尔瑟姆的运营提供资金。2023年9月12日（GLOBE NEWSWIRE）-Dianthus Therapeutics，Inc。（“Dianthus”），一家临床阶段生物技术公司，致力于推进下一代抗体补体疗法，以治疗严重的自身免疫性疾病，今天宣布了DNTH103的正一线1期数据，验证了其作为仅针对C1s蛋白活性形式的选择性经典途径抑制剂的一流潜力。
Additionally, Dianthus will begin trading on the Nasdaq Capital Market today as DNTH, following the successful completion on September 11, 2023 of the previously announced merger with Magenta Therapeutics (“Magenta”). The Phase 1 healthy volunteer study was designed to validate the extended half-life, potent classical pathway inhibition, and potentially differentiated safety profile of DNTH103.
此外，在先前宣布与Magenta Therapeutics（“Magenta”）合并后于2023年9月11日成功完成后，Dianthus将于今天作为DNTH在纳斯达克资本市场开始交易。第一阶段健康志愿者研究旨在验证延长的半衰期，有效的经典途径抑制以及DNTH103潜在差异化的安全性。
Top-line data across seven single and multiple ascending dose cohorts with 52 healthy volunteers confirmed its approximately 60-day half-life.
来自52名健康志愿者的7个单次和多次递增剂量队列的顶线数据证实其大约60天的半衰期。